[ad_1]
Original title: UK approves introduction of new Pfizer coronary vaccine in China Fosun
The new crown vaccine is hitting the market, with Pfizer and BioNTech taking the lead in the UK. On December 2 local time, the UK approved the use of the new corona vaccine jointly developed by Pfizer and BioNTech in Germany. The British government stated: “The government has accepted the recommendation of the British Medicines and Medical Products Regulatory Agency (MHRA) to approve the use of the new corona vaccine from Pfizer / BioNTech. The vaccine will be available throughout the UK from Next week’s priority population includes residents of nursing homes, health and nursing staff. “
Pfizer and BioNTech expect to make more regulatory decisions on a global scale in the coming days and weeks, and are ready to provide vaccine doses after possible regulatory clearance or approval. Vaccine distribution in the UK will be prioritized according to the populations identified in the Joint Committee on Vaccination and Immunization (JCVI). The UK has reportedly ordered 40 million doses of vaccine, enough to vaccinate 20 million people, twice per person.
Ahead of the US Stock Market on December 2, the stock prices of Pfizer (PFE.US) and BioNTech (BNTX.US) rose. As of 5:00 pm Beijing time, Pfizer rose 4.19% to $ 41.06; BioNTech was up 7.51% to $ 122.57.
Ugur Sahin, BioNTech co-founder and CEO, said the UK emergency use authorization marks the first time that ordinary people, other than trial volunteers, have had the opportunity to receive the new corona vaccine. “We believe that the implementation of a vaccination program in the UK will slow down the hospitalization of high-risk groups.”
In July 2020, Pfizer and BioNTech announced an agreement with the UK to provide 30 million doses of BNT162b2 mRNA-based vaccines once emergency use rights are obtained. The agreement was increased to 40 million doses in early October and will be delivered in phases in 2020 and 2021 to ensure fair distribution of vaccines in areas where contracts have been signed.
The two companies have submitted an application for emergency use authorization to the US Food and Drug Administration (FDA) and, after submitting a continuous application to the European Medicines Agency (EMA) and several other agencies regulators from around the world submitted the final conditional Marketing Authorization Application.
Regarding the transportation and storage of Pfizer vaccines, which has attracted a lot of attention, Pfizer said that it has extensive experience and knowledge in cold chain transportation, and has a complete infrastructure to provide vaccines around the world, including the capacity to store vaccine doses of up to 6 monthly Distribution Center. The company’s distributor can quickly ship frozen vials to designated vaccination points when required. This will minimize the need for long-term storage anywhere.
Pfizer is also reportedly planning to purchase an average of 20 aircraft a day from FedEx, UPS and DHL International to complete vaccine delivery. Additionally, Pfizer has also established more warehousing locations in Wisconsin and Germany.
The two companies have developed a specially designed temperature-controlled carrier for their new candidate corona vaccine BNT162b2. The shipper can extend the recommended storage conditions (-70 ° C ± 10 ° C) without using any other equipment and using dry ice. The shipper can maintain the temperature for 10 days unopened, allowing for transport to the world market. Once opened, the vaccination center can use a specially designed charger as a temporary storage solution to maintain the recommended storage conditions (-70 ° C ± 10 ° C) for 30 days and refreeze every 5 days according to the operating instructions. Each sender contains a GPS thermal sensor that can track the location and temperature of each batch of vaccines 24 hours a day, 7 days a week. Once thawed, the vaccine vial can be stored refrigerated (2-8 ° C) for up to 5 days.
“Vaccination under pandemic conditions is expected to proceed quickly and demand is high. The product is expected to not need to be stored anywhere for more than 30 days,” said Pfizer.
At the national level, already in March of this year,Fosun PharmaTo achieve strategic cooperation with BioNTech, the two parties jointly developed and commercialized a novel coronavirus vaccine product based on BioNTech’s proprietary mRNA technology platform in China.
On November 25, BioNTech and Fosun Pharma announced that BNT162b2 will begin a phase II clinical trial with Taizhou and Lianshui, Jiangsu, China. It plans to recruit 960 healthy subjects between the ages of 12 and 85 to evaluate the safety and immunity of the candidate vaccine. Originality, used to support the future application of the vaccine in the China market. Fosun Pharma stated that it is currently actively promoting clinical vaccine research in China and accelerating the domestic market for mRNA nucleic acid vaccines.
A day later, Fosun Pharma released the “Preliminary Plan for Private Issuance of A Shares”, intending to privately issue no more than 128 million shares for specific purposes, and plans to raise 4.983 billion yuan for the preparation of clinical, licensing and product lists of innovative medicines. , Intensive integral base of raw materials and preparations and complementary working capital.
It is worth noting that in this fixed increase plan, Fosun Pharma intends to use 325 million yuan for the new coronavirus mRNA vaccine. However, investors did not accept the fundraising case. On November 26, the closing price of Fosun Pharma was 51.59 yuan per share, down 2.94%. Beijing Daily Full Business Report
Massive information, accurate interpretation, all in the Sina Finance APP
